Understanding the Shifts in Obesity Market Dynamics

DelveInsight's Obesity Market Insights report offers a comprehensive overview of these shifts, encompassing current treatment practices, emerging drugs, market shares of individual therapies, and projections for market size from 2020 to 2034 across the 7MM, including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Request for Sample report @ Obesity Market

Market Overview and Key Takeaways

According to DelveInsight, the obesity market size in the United States reached USD 1.2 billion in 2022. The total prevalent population of obesity in the United States was 114 million cases in 2023, with expectations of an increase by 2034. Prominent pharmaceutical companies such as Novo Nordisk A/S, Pfizer, Boehringer Ingelheim, Eli Lilly and Company, and others are at the forefront of developing novel obesity treatments, poised to enter the market in the upcoming years. These therapies include Oral semaglutide, Danuglipron (PF-06882961), Survodutide (BI 456906), Liraglutide, Cagrilintide, Orforglipron, Setmelanotide, Carbetocin, Pitolisant, DCCR, among others.

Notable developments include the FDA approval of Eli Lilly and Company's ZEPBOUND (tirzepatide) in November 2023, targeting both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) hormone receptors. Additionally, Pfizer's oral GLP-1RA candidate, danuglipron, demonstrated promising results in a Phase IIb clinical trial, showing significant weight reduction in adults with obesity.

Obesity Overview

Obesity is a chronic condition characterized by excessive body fat and overweight, often resulting in metabolic complications beyond mere physical size. It is influenced by genetic predispositions and environmental factors. Severe forms of obesity can arise from mutations in genes related to the leptin-melanocortin axis, such as LEPR, POMC, MC4R, NTRK2, and SIM1. Symptoms include high blood pressure, stretch marks, and a body mass index (BMI) exceeding 30 kg/m², which can exacerbate the risk of various diseases.

Obesity also carries significant social and psychological stigma, leading to discrimination in personal and professional spheres, contributing to low self-esteem and depression. Childhood obesity can lead to similar complications as adult obesity, often with an earlier onset.

Epidemiology and Segmentation

The report highlights a rise in diagnosed prevalent cases of obesity, with the United States accounting for 61% and 66% of cases for adults and children, respectively, in 2023. The report provides an epidemiological analysis for the study period 2020-2034 across the 7MM, segmented into total prevalent cases of obesity, patients seeking help, and treated cases.

Treatment Market

Traditional obesity treatments include weight reduction through healthy eating, increased physical activity, and lifestyle modifications. Weight management programs can be effective, but some individuals struggle to achieve or maintain sufficient weight loss, necessitating alternative therapies like weight-loss medications, devices, or bariatric surgery.

Innovative treatments include ingestible hydrogels that absorb stomach water to induce satiety, vagal nerve blockade using implanted devices to signal fullness to the brain, and gastric aspiration techniques. FDA-approved treatments encompass a variety of drugs such as CONTRAVE (bupropion-naltrexone), SAXENDA (liraglutide), Alli and XENICAL (orlistat), QSYMIA (phentermine-topiramate), IMCIVREE (setmelanotide), and WEGOVY (semaglutide).

Emerging Therapies and Key Companies

Several late-stage therapies are in development, including Oral semaglutide (Novo Nordisk), Danuglipron (Pfizer), Survodutide (Boehringer Ingelheim), and others. These therapies are anticipated to significantly impact the obesity market as they progress through clinical trials and receive regulatory approvals.

For instance, RYBELSUS, an oral GLP-1 RA, is approved in multiple regions for enhancing glycemic control in type II diabetes patients and is undergoing Phase III trials for obesity treatment. Pfizer's danuglipron has shown promise in reducing body weight in obese adults without type II diabetes, furthering its potential as a viable obesity treatment.

Request for Sample report @ Obesity Market

Market Dynamics and Future Outlook

The obesity market is expected to undergo dynamic changes, driven by increased investment in drug research and development and the advent of mobile technologies enhancing intervention possibilities. Key players like Novo Nordisk and Eli Lilly are addressing unmet needs, while governmental and non-governmental efforts are raising awareness and expanding market opportunities.

Despite these advancements, challenges remain. There is no consensus on the best obesity treatment, and conventional interventions often fail long-term. Disparities in disease staging systems, high costs, and comorbidities complicate obesity management. Additionally, the economic burden and impact on patients' quality of life, coupled with issues like market access, reimbursement, and healthcare specialist shortages, pose significant hurdles.

Conclusion

The obesity market is on the cusp of significant transformation, with emerging therapies poised to offer new standards of care and drive economic growth. While challenges persist, the continued focus on innovative treatments and comprehensive management strategies holds promise for better addressing the obesity epidemic and improving patient outcomes.

Trending Reports: